Substituted triazolo bicyclic compounds as PDE2 inhibitors
申请人:MERCK SHARP & DOHME CORP.
公开号:US10357481B2
公开(公告)日:2019-07-23
The present invention is directed to substituted triazolo bicyclic compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
本发明涉及式 I 的取代三唑并双环化合物,其可作为治疗剂用于治疗与磷酸二酯酶 2 (PDE2)相关的中枢神经系统疾病。本发明还涉及使用此类化合物治疗神经和精神疾病,如精神分裂症、精神病、帕金森病、帕金森病痴呆(PDD)或亨廷顿病,以及与纹状体功能低下或基底节功能障碍相关的疾病。
Hexitol derivatives
申请人:KYOWA HAKKO KOGYO CO., LTD.
公开号:EP0393574B1
公开(公告)日:1996-01-31
STANOVNIK B.; URLEB U.; TISLER M., MONATSH. CHEM., 118,(1987) N 5, 601-606
作者:STANOVNIK B.、 URLEB U.、 TISLER M.
DOI:——
日期:——
US5053408A
申请人:——
公开号:US5053408A
公开(公告)日:1991-10-01
An unequivocal synthesis of some substituted 1,2,4-triazolo[1,5-a]pyrimidines